NYSE:KVUE

Kenvue Reports First Quarter 2024 Results

Retrieved on: 
Tuesday, May 7, 2024
Medical Supplies, Health, Health Technology, Other Health, General Health, Biotechnology, TSA, Johnson & Johnson, Interest, Organic, Culture, Oral hygiene, Inc., ID, Absorption, GAAP, Lunar phase, Growth, KVUE

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal first quarter ended March 31, 2024.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal first quarter ended March 31, 2024.
  • Approximately two points of the volume contraction was attributed to the expected lapping of one-time retailer inventory re-builds in the first quarter of 2023 and impacts of retailer inventory reduction in the first quarter of 2024, which the Company expects to continue through the second quarter of 2024.
  • Kenvue continues to expect full year 2024 Adjusted diluted earnings per share to be in the range of $1.10 - $1.20.
  • As previously announced, Kenvue will host a conference call with investors to discuss its first quarter results at 8:30 a.m. Eastern Time.

Kenvue Declares Quarterly Cash Dividend

Retrieved on: 
Thursday, April 25, 2024
General Health, Home Goods, Health, Retail, Medical Supplies, Inc., KVUE

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the second quarter of $0.20 per share on the Company’s common stock.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the second quarter of $0.20 per share on the Company’s common stock.
  • The second quarter dividend is payable on May 22, 2024 to shareholders of record as of the close of business on May 8, 2024.

Kenvue to Announce First Quarter 2024 Results on May 7, 2024

Retrieved on: 
Friday, April 5, 2024
Biotechnology, General Health, Other Health, Health, Medical Supplies, ID, Webcast, KVUE, Inc.

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the first quarter ending March 31, 2024, before market open on May 7, 2024.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the first quarter ending March 31, 2024, before market open on May 7, 2024.
  • The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results.
  • The conference call can be accessed by dialing 888-672-2415 from the U.S. or +1 646-307-1952 from international locations.
  • A live webcast of the conference call will be available at investors.kenvue.com .

Kenvue to Showcase 22 New Sets of Clinical Data at American Academy of Dermatology Association Meeting

Retrieved on: 
Thursday, March 7, 2024
Retail, Health, Home Goods, Other Health, Clinical Trials, General Health, Cream, Name, Skin, Woman, Efficacy, Psoriasis, Pigment, Education, Quality of life, Dermatology, Skin care, Risk, AAD, Itch, Dermatitis, Science, San Diego Convention Center, Inc., Theatre, American Academy, Cosmetics

Kenvue will also offer hands-on experiences in exhibit-floor Booth 2511, featuring products that are household names, including those from the Neutrogena®, Aveeno®, NeoStrata®, Lubriderm®, BAND-AID® Brand and Rogaine®1 portfolios.

Key Points: 
  • Kenvue will also offer hands-on experiences in exhibit-floor Booth 2511, featuring products that are household names, including those from the Neutrogena®, Aveeno®, NeoStrata®, Lubriderm®, BAND-AID® Brand and Rogaine®1 portfolios.
  • Additional data to be presented at AAD demonstrates the benefits of Kenvue’s formulations for skin hydration, sun protection and acne control.
  • Demonstrating the Clinical Effectiveness of Mineral Sunscreens in Protecting the Skin Against Ultraviolet A (UVA) Radiation-Induced Pigmentation; Shyr TC, et al.
  • On Friday and Saturday, Kenvue experts and key opinion leaders will also host R&D Theater presentations in the booth.

Kenvue to Present at the Consumer Analyst Group of New York Conference on February 23, 2024

Retrieved on: 
Tuesday, February 13, 2024
Home Goods, Pharmaceutical, General Health, Health, Convenience Store, Cosmetics, Retail, Other Health, KVUE, Inc., Conference

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced Thibaut Mongon, Chief Executive Officer, and Paul Ruh, Chief Financial Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference in Boca Raton, Florida, on Friday, February 23, 2024, at 10:00 a.m. Eastern Time.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced Thibaut Mongon, Chief Executive Officer, and Paul Ruh, Chief Financial Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference in Boca Raton, Florida, on Friday, February 23, 2024, at 10:00 a.m. Eastern Time.
  • A live webcast of the session will be available at investors.kenvue.com and a replay will be available on the same website following the event.

Kenvue Reports Full Year and Fourth Quarter 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Home Goods, Medical Supplies, Health, Medical Devices, Consumer, Other Consumer, Retail, Other Health, GAAP, Inc., Absorption, Interest, Organic, Cough, KVUE, ID, Culture, Insurance

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced financial results for the fiscal full year and fourth quarter ended December 31, 2023.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced financial results for the fiscal full year and fourth quarter ended December 31, 2023.
  • Fourth quarter Net sales decreased 2.7% vs a 0.9% increase in the prior year period.
  • Interest expense, net was $250 million for the year on a reported basis, and $96 million for fourth quarter 2023.
  • As previously announced, Kenvue will host a conference call with investors to discuss its fourth quarter results at 8:30 a.m. Eastern Time.

KENVUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Kenvue Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, January 27, 2024
Risk, Telephone, Register, IPO, Prospectus, P.C, Phenylephrine, KVUE

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kenvue Inc. (NYSE: KVUE) on behalf of long-term stockholders following a class action complaint that was filed against Kenvue on October 9, 2023 with a Class Period pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Kenvue’s initial public offering (the “IPO” or “Offering”).

Key Points: 
  • NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kenvue Inc. (NYSE: KVUE) on behalf of long-term stockholders following a class action complaint that was filed against Kenvue on October 9, 2023 with a Class Period pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Kenvue’s initial public offering (the “IPO” or “Offering”).
  • Our investigation concerns whether the board of directors of Kenvue have breached their fiduciary duties to the company.
  • If you are a long-term stockholder of Kenvue, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected] , by telephone at (212) 355-4648, or by filling out this contact form .
  • There is no cost or obligation to you.

Kenvue Declares Quarterly Cash Dividend

Retrieved on: 
Thursday, January 25, 2024
Cosmetics, Medical Supplies, Retail, Health, Home Goods, Pharmaceutical, Inc., KVUE

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter of $0.20 per share on the Company’s common stock.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter of $0.20 per share on the Company’s common stock.
  • The first quarter dividend is payable on February 28, 2024 to shareholders of record as of the close of business on February 14, 2024.

Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024

Retrieved on: 
Friday, January 5, 2024
Retail, Home Goods, General Health, Health, Webcast, ID, KVUE, Inc.

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024.
  • The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results.
  • The conference call can be accessed by dialing 888-660-5501 from the U.S. or 646-960-0416 from international locations.
  • A live webcast of the conference call will be available at https://investors.kenvue.com .

KVUE DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action First Filed by the Firm - KVUE

Retrieved on: 
Saturday, December 2, 2023
Titan, Phenylephrine, Court, Register, KVUE, Plaintiff, Prospectus, Advertising, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.